Oct. 24 at 11:34 AM
$GANX National MJFF commercials, Washington Post article, and now Cantor holding KOL events and issuing notes, all about Parkinson’s.
National epidemic and a primary focus of all large pharma. EVERY one of them per my former top pharma executives comments I shared yesterday. They are all surely at the table,
$1B for the first disease modifying drug for PD and likely a host of other neurodegenerative diaeases. is a mere rounding error for all of them.
Patent cliff approaching and pipelines thin, against a now improving macro biotech market. Look for a flurry of M&A imo.
